BioSpace News Archive

FDA

Agenus Withdraws BLA for PD1 as Big Dog Merck Corners the Indication

Lexington, Mass.-based Agenus withdrew its Biologics License Application for balstilimab from the U.S. FDA. The drug is a PD-1 inhibitor or checkpoint inhibitor.

October 22, 2021
·
3 min read
·
Mark Terry
Bio NC

Clinical Catch-Up: October 18-22

It was yet another busy week for clinical trial news. Here’s a look.

October 22, 2021
·
11 min read
·
Mark Terry
Myotonic Muscular Dystrophy Market Size will Observe Substantial Growth by 2025

Muscular dystrophy, or myotonic dystrophy, refers to a series of long-term hereditary illnesses that affect functions of the muscle.

October 22, 2021
·
7 min read
C-reactive Protein Testing Market is projected to experience significant growth opportunities to 2030

Plasmonic Nanoparticles have been among the significant tools that are applied for biosensing applications because of their versatile optical properties.

October 22, 2021
·
4 min read
Sales of Dental Endodontics to Exceed US$ 3 Bn through 2031

Fact.MR – A Market Research and Competitive Intelligence Provider: Globally the sales of dental endodontics are estimated to grow 2.3 times through 2021.

October 22, 2021
·
8 min read
Anti-Mullerian Hormone (AMH) Testing Market: Polycystic Ovary Syndrome (PCOS) Evaluation to Lead Global Market

The anti-Müllerian hormone (AMH) is a glycoprotein-based hormone that is used to determine fertility levels

October 22, 2021
·
4 min read
Nexstim Releases the New NBS5+ in the United States

Nexstim Plc announces the launch of a new navigated transcranial magnetic stimulation system configuration in the United States, to further strengthen competitive advantage in this market.

October 22, 2021
·
2 min read
2021 Bio-enzyme Application Explorer Summit held in Chengdu

The biochemical pharmaceutical industry is facing unprecedented opportunities and challenges with the changing economic and policy environment in China and abroad.

October 22, 2021
·
7 min read
Egle Therapeutics Raises 40 Million € Series a to Develop First-In-Class T-regulatory Cells Therapies Based On Treg-starvers

Egle Therapeutics SAS, an emerging biotechnology company focused on developing First-In-Class immunotherapies targeting immune suppressor regulatory T-cells for oncology and autoimmune diseases, announces that it has completed a €40M Series A financing.

October 22, 2021
·
7 min read
QIAGEN Strengthens UK Footprint With Move to New Manchester Facilities

QIAGEN today announced the completion of the move of its European Center of Excellence for Precision Medicine into facilities in Manchester’s CityLabs 2.0, a new genomics campus developed with Health Innovation Manchester.

October 22, 2021
·
6 min read